title: High-dose interleukin-2 in metastatic renal cell carcinoma.
authors.forename: Ricardo
authors.initials: R
authors.lastname: Fernández-Rodríguez
authors.forename: Gonzalo López
authors.initials: GL
authors.lastname: de Argumedo
authors.forename: Juan Manuel
authors.initials: JM
authors.lastname: Mañé
authors.forename: Alberto
authors.initials: A
authors.lastname: Muñoz
authors.forename: Josefa
authors.initials: J
authors.lastname: Ferreiro
authors.forename: Natalia
authors.initials: N
authors.lastname: Fuente
authors.forename: Guillermo
authors.initials: G
authors.lastname: López-Vivanco
mesh_terms: D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology* / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D005260:Female; D006801:Humans; D007376:Interleukin-2 / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology* / Q000601:surgery; D008297:Male; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D009392:Nephrectomy / Q000379:methods; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D012016:Reference Values; D018570:Risk Assessment; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D007376:Interleukin-2